Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05727787 · ClinicalTrials.gov registry record · NA

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

A NA study of Liver Cancer, sponsored by University of Kansas Medical Center.

Recruiting
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT05727787 is a NA study of Liver Cancer that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 18 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05727787, a NA study of Liver Cancer, is actively recruiting participants, sponsored by University of Kansas Medical Center.

RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique. Based on trials using this type of radiation in other cancers demonstrating low toxicity rates even with very high radiation doses and high efficacy, it is likely that vGRID therapy in this trial will be well tolerated and allow dose escalation beyond currently common doses for liver tumors.

Conditions Studied

Interventions

  • RADIATION Stereotactic Body Radiation Treatment

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-02-23
Est. Completion 2028-08-31
Phase NA

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT05727787

The ClinicalTrials.gov registry entry for NCT05727787 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Body Radiation Treatment is the first listed.

NCT05727787 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT05727787 about?

NCT05727787 is a clinical study titled "vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC". This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique. Based on trials using this type of radiation in other cancers demonstrating low toxicity rates even with very high radiation doses and high e...

What is the current status of trial NCT05727787?

This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2023-02-23. Estimated completion is 2028-08-31.

What conditions does trial NCT05727787 study?

This clinical trial studies the following conditions: Liver Cancer.

What interventions are being tested in trial NCT05727787?

The interventions under investigation include: Stereotactic Body Radiation Treatment (RADIATION).

Who is sponsoring clinical trial NCT05727787?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05727787 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.